The Biosynthesis of Cannabinoids
Posted 6th May 2020 by Joshua Sewell
We recently spoke to Jeremy Friedberg, CSO of LAVVAN, a company pioneering the biosynthesis of cannabinoids. The conversation was recorded as a podcast, which can be found here.
The case for biosynthesis: 5 problems with cannabinoids derived from plant cultivation
Posted 25th February 2020 by Joshua Sewell
As we look at the current and future market demands for cannabinoid ingredients, large consumer buyers are focused on purity, consistency and stability of supply. For a host of reasons, cannabinoid suppliers will find it extraordinarily difficult to meet this demand with plant-based production systems.
5 key requirements for unleashing innovation in the cannabis industry
Posted 21st February 2020 by Joshua Sewell
The cannabis industry faces a systemic problem where the legal nomenclature used to distinguish varietals of Cannabis Sativa is known to be unrelated to the genetic identity of the plant.1 Cannabis plants being bought and sold under any specific trade name can be genetically unrelated and may not even have a shared cultivation history.
11 ways to enable more UK patients to benefit from medicinal cannabis
Posted 14th February 2020 by Joshua Sewell
Medicinal cannabis was legalised in the UK in November 2018, yet there have been fewer than ten new prescriptions made through the NHS. Most of the prescriptions made have been private, and are financially out of reach for most patients, costing up to £2000 per month.